In previous studies employing interferons (IFNs) in the treatment of chronic hepatitis C, there have been few reliable predictors of sustained responses. We retrospectively evaluated the predictive value of hepatitis C virus (HCV)-RNA measurements in the first few months during consensus interferon
Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
✍ Scribed by Kunihiko Hino; Shigehiko Sainokami; Kazumi Shimoda; Shiro Iino; Yu Wang; Hiroaki Okamoto; Yuzo Miyakawa; Dr. Makoto Mayumi
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 708 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Interferon induces remission in about 50% of patients with chronic hepatitis C, but it is difficult to predict which patients will respond. Host and viral factors were evaluated for correlation with response to interferon in patients with chronic hepatitis C. Recombinant interferon alpha‐2b with a total dose of 480‐560 million units was given to 136 patients, of whom 74 (54%) responded. Genotypes of hepatitis C virus (HCV) in sera, I, II, III, IV, and V, were determined by poly‐merase chain reaction (PCR) with type‐specific primers. In 72 patients, pretreatment levels of HCV RNA were titrated by PCR in serial tenfold dilutions of RNA extracted from serum. Response to interferon occurred in 34 (40%) of 85 patients infected with HCV of genotype II, less frequently than in 22 (85%) of 26 with genotype III (P < 0.001) or in 7 (70%) of 10 with genotype IV. Of 51 patients with genotype II HCV, 6 of 8 (75%) with HCV RNA titers <10^6^ responded, more frequently than 4 of 43 (9%) with titers ≥ 10^6^ (P < 0.001). Responders were younger than non‐responders (45.7 ± 11.7 vs. 50.3 ± 9.6 yr) and had received transfusions less frequently (26/74 or 35% vs. 37/62 or 60%, P < 0.01). Response to interferon correlated inversely with the severity of liver histopathology. These results indicate that response to interferon is influenced by HCV genotypes and pretreatment levels of HCV RNA in serum. © 1994 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
To investigate the involvement of T-cell response against hepatitis C virus (HCV) antigens in viral clearance after interferon therapy, we measured interleukin-2 (IL-2) production by peripheral mononuclear cells in response to HCV core in patients with chronic hepatitis C. In a cohort of 43 patients
CORRESPONDENCE 1287 tive anions determine the potential for crystal precipi-though the location within the stone is not identified. Thus, their data would seem to confirm our findings tation within bile. Certain disease states predispose and be in conflict with the statement in their letter to supe
## Abstract The use of quantitative assays for hepatitis C virus specific antibodies (anti‐HCV) as a prognostic marker was evaluated in 31 patients with chronic hepatitis C treated with interferon (IFN). Changes in titers of serum HCV‐RNA and anti‐HCV antibodies; anti‐C11 (anti‐core), anti‐C100 (an
Recent studies performed in Japan have suggested that hepatitis C virus (HCV) genome heterogeneity might be taken as a predictive virological parameter of response to interferon alfa (IFN-alpha) treatment. However, there is presently no information on the impact of this virological parameter in pati
## Abstract Genotyping of 179 consecutive Japanese chronic hepatitis C patients was carried out based on the variation in the hepatitis C virus (HCV) core gene. The results were correlated with clinical features and antibody responses toward specific HCV proteins deduced from the nucleotide sequenc